Medexprim
BC Platforms provides AI-enabled data platforms and a global real-world data network spanning 187M+ patients to pharmaceutical companies and healthcare organizations, supporting drug development, regulatory submissions, and precision medicine research across multi-modal clinical, genomic, and imaging data.
- Company typePrivate
- Founded1997
- HeadquartersLabège, France
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Medexprim does
BC Platforms is a privately held health data and analytics company founded in 1997 that provides AI-enabled platforms and a global real-world data network to pharmaceutical companies and healthcare organizations engaged in drug development, regulatory submission, and precision medicine research. The company addresses the fragmentation of multi-modal healthcare data — spanning clinical, genomic, imaging, and multi-omics sources — through an integrated portfolio of five core products: BC Unify (AI-driven data mastering that ingests, harmonizes, transforms, and enriches multi-modal data), BC Catalyst (a prompt-based precision medicine platform for cohort identification, biomarker discovery, and population health analysis), BC Image (AI-driven medical image extraction, de-identification, and processing with GDPR-compliant workflows), BC Mosaic (a trusted research environment hosted on AWS Marketplace), and BC Data (a curated global real-world data network spanning oncology, neurology, rare diseases, immunology, and other therapeutic areas). The underlying technology architecture is AI-enabled and federated, including federated machine learning integrated through a partnership with Flower Labs, enabling collaborative research across distributed data sources without centralizing patient data.
The commercial model combines enterprise platform licensing and subscriptions with annual billing (quote-based, not publicly disclosed), revenue-sharing programs in which the 150+ healthcare organization data partners share in monetization of contributed data, and scientific and technology consulting services for evidence generation and AI implementation. GTM is anchored in direct enterprise field sales targeting top 20 pharmaceutical companies and 150+ healthcare organizations, augmented by AWS Marketplace distribution for BC Mosaic and an event-driven demand-generation layer across industry conferences and webinars. The company meets EHDS and GDPR+ standards, supports 20+ FDA/EMA regulatory submissions, and operates with a global footprint skewed outside the US (greater than 90% of accessible patient data is non-US). No parent entity, external investor roster, or disclosed funding rounds appear in the source data despite 25+ years of operation.
Medexprim firmographics
Firmographics- Name
- Medexprim
- Legal name
- BC Platforms
- Website
- https://medexprim.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BC Platforms provides AI-enabled data platforms and a global real-world data network spanning 187M+ patients to pharmaceutical companies and healthcare organizations, supporting drug development, regulatory submissions, and precision medicine research across multi-modal clinical, genomic, and imaging data.
- Ownership category
- akta.pro rank
Medexprim industry classification
Industry- Product category
- Healthcare Real-World Data Analytics
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where Medexprim is headquartered
LocationHeadquarters
- HQ city
- Labège
- HQ country
- France
- HQ region
- Europe
Markets served
Medexprim business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Data Platform Licensing and Subscription: BC Platforms provides its AI-driven data platforms (BC Unify, BC Catalyst, BC Image, BC Mosaic) as solutions to pharmaceutical companies and healthcare organizations. The business model involves licensing access to platforms and data services that help reduce development timelines, enable personalized therapies, and support regulatory submissions. The company emphasizes a trusted partner relationship with revenue-sharing programs for data partners.
- Data Partner Revenue Sharing: Healthcare organizations that contribute data to BC Platforms' global network participate in revenue-sharing programs. This creates a mutually beneficial ecosystem where data partners harmonize, anonymize, and commercialize their data while receiving a share of resulting value.
- Scientific & Technology Consulting: Expert consulting services for evidence generation, data integration, scalable analytics, and AI implementation support the core platform business and provide additional service revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise licensing with customized pricing based on scope and requirements |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
Medexprim product offering
Product offeringCore offering
Medexprim provides AI-enabled software platforms and a global real-world data network that allow pharmaceutical companies and healthcare organizations to ingest, harmonize, analyze, and collaborate on multi-modal clinical, genomic, imaging, and multi-omics data across the drug development lifecycle. Its portfolio includes data mastering (BC Unify), precision medicine cohort discovery (BC Catalyst), medical image processing (BC Image), trusted research environments (BC Mosaic), and curated real-world datasets (BC Data), supplemented by scientific and technology consulting services.
Product overview
BC Platforms offers a unified platform-plus-modules architecture comprising five core AI-enabled products: BC Unify (AI-driven data mastering platform), BC Catalyst (prompt-based precision medicine/cohort discovery), BC Image (medical image processing), BC Mosaic (trusted research environment on AWS), and BC Data (global real-world data network). These integrated solutions work together to enable end-to-end data provisioning, analytics, and collaboration across the drug development lifecycle, from data harmonization through secure research environments to actionable insights.
Differentiator
Problem solved
Functional benefit
Brands
- BC Unify: AI-driven, end-to-end data mastering platform that ingests, harmonizes, transforms, and enriches multi-modal data.
- BC Catalyst
- BC Image
- BC Mosaic
- BC Data
Products and services
- BC Unify AI-driven, end-to-end data mastering platform that ingests, harmonizes, transforms, and enriches multi-modal data (clinical, EMRs, eCRFs, labs, multi-omics, imaging) to support advanced use cases across the drug development lifecycle for pharmaceutical and healthcare customers.
- BC Catalyst AI-powered, prompt-based precision medicine platform for cohort building, biomarker discovery, and population health insights that makes complex genomic and real-world clinical data actionable across the drug lifecycle for pharmaceutical researchers.
- BC Image AI-driven, end-to-end platform that automates medical image extraction, de-identification, and processing, streamlining workflows for large image datasets while maintaining GDPR compliance for pharmaceutical and clinical research users.
- BC Mosaic Trusted research environment (TRE) built for clinical, genomic, and multi-omics studies, enabling secure collaboration and analysis with regulatory-compliant audit trail, bioinformatics capacity, and data visualization tools; available on AWS Marketplace.
- BC Data Global real-world data network providing curated datasets spanning clinical data, EMRs, eCRFs, labs, multi-omics, and imaging data across oncology, neurology, rare diseases, immunology, and other therapeutic areas for pharmaceutical and research customers.
- Scientific & Technology Consulting Expert consulting services providing guidance on evidence generation, data integration, scalable analytics, and AI implementation across healthcare and life sciences for pharmaceutical companies and healthcare organizations.
Quantifiable outcome
- Reduces development timelines compared to typical real-world data research at this scale
- +3 more outcomes
Companies that use Medexprim
Customer profileNamed customers15 records
Segments2 records
Ideal customer profiles2 records
Medexprim technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability8 records
Feature6 records
Medexprim partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, secondary and minor.
- Amazon Web Services (AWS)coreBC Platforms has signed a Strategic Collaboration Agreement with AWS to enhance the speed and scale of trusted research environments. The collaboration focuses on scaling secure, AI-powered research environments for healthcare and life sciences innovation. BC Mosaic is available on AWS Marketplace as part of this partnership.
- Flower LabssecondaryBC Platforms partners with Flower Labs to enable federated machine learning across trusted research environments. The partnership integrates the Flower Framework within BC Platforms' TREs, allowing collaborative AI model training without centralizing data, enhancing privacy-preserving machine learning capabilities.
- University of British ColumbiasecondaryAcademic research partnership for advancing healthcare research through multi-modal data collaboration.
- Health Data Research UK (HDRUK)secondaryPartnership with UK health data research organization to support research initiatives and data sharing.
- Imperial College Healthcare NHS TrustsecondaryNHS trust partnership supporting research data collaboration and precision medicine initiatives.
- University of Tartu Estonian Genome CentersecondaryGenomics data partnership contributing to the global data network for research purposes.
- Medical University of Graz BiobanksecondaryBiobank data partnership contributing to research-ready multi-modal data availability.
- NHS University Hospital SouthamptonsecondaryNHS foundation trust partnership for research data collaboration and clinical studies support.
- Institut Gustave RoussysecondaryLeading French cancer research institute partnership for oncology data and precision medicine research.
- Uniklinikum WurzburgsecondaryGerman university hospital partnership for clinical research data collaboration.
- Hôpital FochsecondaryFrench hospital partnership contributing to research data network.
- Technology Industries of FinlandminorIndustry association partnership supporting technology and innovation ecosystem.
Scale indicators7 records
Recent moves3 records
Expansion highlights5 records
Medexprim competitors and assessment
Company assessmentBroad incumbents
- Tempus Labs: Tempus operates a large AI-enabled precision medicine data platform spanning clinical, genomic, and imaging data with deep pharma partnerships, broadly comparable to BC Platforms' data and AI capabilities. It is a significantly larger US-centric incumbent with broader oncology focus.
- Health Catalyst: Health Catalyst provides healthcare data and analytics infrastructure to providers and life sciences organizations, overlapping with BC Platforms' healthcare segment in anonymization, monetization, and research enablement. It is a broader incumbent serving health systems rather than specializing in pharma R&D.
- IQVIA: IQVIA is a global leader in clinical research, real-world evidence, and healthcare data analytics, broadly competing with BC Platforms' pharma R&D and RWE offerings. It operates a much larger portfolio across the drug development lifecycle, including its own EDC/CTMS stack.
- Flatiron Health: Flatiron Health provides oncology-specific real-world data and EHR-linked analytics for pharma and providers, overlapping with BC Platforms' oncology RWD and clinical data offerings within BC Data. It is a broader incumbent with deeper US oncology data assets.
- Medidata Solutions: Medidata (Dassault Systèmes) provides clinical trial informatics including EDC, CTMS, and eCOA as part of a broader life sciences platform, overlapping with BC Platforms' clinical trial data capabilities in BC Mosaic. It is a much larger incumbent serving the same top-20 pharma customer base.
Direct peers
- Owkin: Owkin is a federated AI platform for healthcare and life sciences that enables collaborative model training without moving patient data, similar to BC Platforms' federated learning capabilities. It targets the same pharma R&D customers and is a direct competitor in privacy-preserving clinical/genomic AI.
- TriNetX: TriNetX operates a global real-world data network of healthcare organizations for clinical research and trial feasibility, closely comparable to BC Platforms' BC Data network. It serves pharma with harmonized EHR data and network-based cohort discovery, overlapping with BC Catalyst use cases.
- DNAnexus: DNAnexus provides a cloud-based genomics and multi-omics data platform with strong pharma adoption, comparable to BC Platforms' multi-omics data capabilities within BC Data and the bioinformatics capacity of BC Mosaic. Both serve genomics-driven pharma R&D workflows.
- Datavant: Datavant provides health data connectivity and de-identification infrastructure enabling secure linking of clinical and research datasets, comparable to BC Platforms' data harmonization and de-identification capabilities within BC Unify and BC Image. It serves similar pharma and healthcare data partner ecosystems.
- Lifebit: Lifebit offers a federated genomics and trusted research environment platform for life sciences, very comparable to BC Platforms' BC Mosaic TRE and federated learning architecture. Both target pharma and genomics research customers seeking secure, compliant cross-institution analysis.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Medexprim social profiles
Digital presenceMedexprim compliance and trust
Trust signalCompliance2 records
Medexprim financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medexprim leadership team
Management profileNumber of profiles
Medexprim subsidiaries and ownership
Company hierarchySubsidiaries5 records
Medexprim funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medexprim M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medexprim
What does Medexprim do?
Medexprim provides AI-enabled software platforms and a global real-world data network that allow pharmaceutical companies and healthcare organizations to ingest, harmonize, analyze, and collaborate on multi-modal clinical, genomic, imaging, and multi-omics data across the drug development lifecycle. Its portfolio includes data mastering (BC Unify), precision medicine cohort discovery (BC Catalyst), medical image processing (BC Image), trusted research environments (BC Mosaic), and curated real-world datasets (BC Data), supplemented by scientific and technology consulting services.
Is Medexprim a public or private company?
Medexprim is a private company. It is classified as unknown and is currently operating.
When was Medexprim founded?
Medexprim was founded in 1997. It employs 11 to 50 people.
Where is Medexprim based?
Medexprim is headquartered in Labège, France, in the Europe region.
How does Medexprim make money?
Three revenue lines are on record. Data Platform Licensing and Subscription is the primary driver. The others are data Partner Revenue Sharing and scientific & Technology Consulting.
Who are Medexprim's main competitors?
Broad incumbents on record are Tempus Labs, Health Catalyst, IQVIA, Flatiron Health and Medidata Solutions. Direct peers are Owkin, TriNetX, DNAnexus, Datavant and Lifebit.
Does Medexprim have an API?
No public API is recorded for Medexprim.
What industry is Medexprim in?
Medexprim's product category is Healthcare Real-World Data Analytics. Its primary akta.pro industry code is HLAGAJAF, Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 5132 and its SIC code is 7372.